About ZebiAI
ZebiAI is a Healthcare company based in Waltham (United States) founded in 2019 by Richard Wagner, and was acquired by Relay Therapeutics in April 2021. AI solutions for small molecule drug discovery are provided. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include Formation Bio, AbSci and BigHat; 3 of its 3 listed competitors have raised funding.
Company details
ZebiAI was founded in 2019 and is based in Waltham, United States. Machine learning algorithms are utilized by the company to identify potential clinical candidate molecules and predict their pharmaceutical properties within the small molecule drug discovery sector. Operations focus on AI-driven tools for biotech and pharmaceutical applications. Partnerships are maintained with entities including X-Chem, Google, and SGC to support these efforts.
- Headquarters Waltham, United States
- Founders Richard Wagner
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website zebiai.com
- Acquired by Relay Therapeutics (Apr 2021)
- Investors
- Acquired byRelay Therapeutics
(Apr 2021)
Investors in ZebiAI
ZebiAI has secured backing from 1 investor. Prominent investors backing the company include Relay Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drug discovery platform is developed to study protein motion. | 2016 | relaytx.com | Cambridge, United States |
Investor details for ZebiAI
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ZebiAI
7 people are tracked at ZebiAI (6 in leadership, 1 in board & advisors).
| Name | Role | Group |
|---|---|---|
Richard Wagner | Founder & Director | Leadership |
Rafa Gomez-Bombarelli | Chief Learning Officer | Leadership |
Ed Koval | Chief Business Officer | Leadership |
Brant Binder | President | Leadership |
John Cuozzo | SVP and Head of Drug Discovery | Leadership |
Brian Goldman | SVP and Chief Computation Officer | Leadership |
Christelle Huguet | Chair, Scientific Advisory Board | Board & advisors |
Complete people profiles for ZebiAI
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ZebiAI
2 dated milestones of ZebiAI across 2 years, from founding to its latest funding, stage changes and deals.
- Founded ZebiAI is founded.
- Exit Acquired by Relay Therapeutics.
Competitors of ZebiAI
ZebiAI has 3 listed competitors in our database, 3 of them funded. They include Formation Bio, AbSci and BigHat.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| formation.bio | 2016 | New York, United States | $608.25M | AI-powered drug discovery platform for various diseases | ||
| absci.com | 2011 | Vancouver, United States | $227.56M | 256 | AI-based technology is used for recombinant protein production in therapeutics. | |
| bighatbio.com | 2019 | San Carlos, United States | $148.41M | Antibody therapies are developed through machine learning and synthetic biology. |
Detailed competitors of ZebiAI
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as ZebiAI (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zebiai
Complete news archive for ZebiAI
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ZebiAI
ZebiAI was founded in 2019.
ZebiAI is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
ZebiAI was founded in 2019 and is based in Waltham, United States. Machine learning algorithms are utilized by the company to identify potential clinical candidate molecules and predict their pharmaceutical properties within the small molecule drug discovery sector. Operations focus on AI-driven tools for biotech and pharmaceutical applications. Partnerships are maintained with entities including X-Chem, Google, and SGC to support these efforts.
ZebiAI's top competitors include Formation Bio, BigHat and AbSci.
ZebiAI has 1 investor. Key investors include Relay Therapeutics.
Yes. ZebiAI was acquired by Relay Therapeutics in April 2021.